JP2015506179A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015506179A5 JP2015506179A5 JP2014554791A JP2014554791A JP2015506179A5 JP 2015506179 A5 JP2015506179 A5 JP 2015506179A5 JP 2014554791 A JP2014554791 A JP 2014554791A JP 2014554791 A JP2014554791 A JP 2014554791A JP 2015506179 A5 JP2015506179 A5 JP 2015506179A5
- Authority
- JP
- Japan
- Prior art keywords
- point mutation
- amino acid
- acid sequence
- polynucleotide
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 54
- 229920001184 polypeptide Polymers 0.000 claims description 48
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 48
- 231100000590 oncogenic Toxicity 0.000 claims description 27
- 230000002246 oncogenic effect Effects 0.000 claims description 27
- 230000003612 virological effect Effects 0.000 claims description 25
- 239000002157 polynucleotide Substances 0.000 claims description 21
- 102000040430 polynucleotide Human genes 0.000 claims description 21
- 108091033319 polynucleotide Proteins 0.000 claims description 21
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 20
- 230000000890 antigenic effect Effects 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 16
- 230000028993 immune response Effects 0.000 claims description 14
- 230000036039 immunity Effects 0.000 claims description 14
- 239000002773 nucleotide Substances 0.000 claims description 12
- 125000003729 nucleotide group Chemical group 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 231100001223 noncarcinogenic Toxicity 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 5
- 230000035772 mutation Effects 0.000 claims 21
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 208000035269 cancer or benign tumor Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 9
- 241000700605 Viruses Species 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 238000000034 method Methods 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 1
- 230000010782 T cell mediated cytotoxicity Effects 0.000 description 1
- 230000009227 antibody-mediated cytotoxicity Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 231100001222 nononcogenic Toxicity 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261590089P | 2012-01-24 | 2012-01-24 | |
| US61/590,089 | 2012-01-24 | ||
| PCT/US2013/022696 WO2013112549A1 (en) | 2012-01-24 | 2013-01-23 | Polynucleotides for treating oncogenic viral polypeptide positive tumors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017188121A Division JP6655051B2 (ja) | 2012-01-24 | 2017-09-28 | 発癌性ウイルスポリペプチド陽性腫瘍治療用ポリヌクレオチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015506179A JP2015506179A (ja) | 2015-03-02 |
| JP2015506179A5 true JP2015506179A5 (enExample) | 2016-03-10 |
| JP6219849B2 JP6219849B2 (ja) | 2017-10-25 |
Family
ID=48873849
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014554791A Active JP6219849B2 (ja) | 2012-01-24 | 2013-01-23 | 発癌性ウイルスポリペプチド陽性腫瘍治療用ポリヌクレオチド |
| JP2017188121A Active JP6655051B2 (ja) | 2012-01-24 | 2017-09-28 | 発癌性ウイルスポリペプチド陽性腫瘍治療用ポリヌクレオチド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017188121A Active JP6655051B2 (ja) | 2012-01-24 | 2017-09-28 | 発癌性ウイルスポリペプチド陽性腫瘍治療用ポリヌクレオチド |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US9492526B2 (enExample) |
| EP (2) | EP3269387B1 (enExample) |
| JP (2) | JP6219849B2 (enExample) |
| KR (1) | KR102195196B1 (enExample) |
| CN (2) | CN110042110A (enExample) |
| DK (1) | DK2806889T3 (enExample) |
| ES (1) | ES2646590T3 (enExample) |
| HK (1) | HK1203833A1 (enExample) |
| IN (1) | IN2014DN06118A (enExample) |
| WO (1) | WO2013112549A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10722564B2 (en) | 2014-11-13 | 2020-07-28 | Université de Genéve | Tri-segmented arenaviruses as vaccine vectors |
| CN107921117B (zh) | 2015-06-10 | 2022-06-07 | 霍欧奇帕生物科技有限公司 | Hpv疫苗 |
| US11214598B2 (en) | 2015-11-04 | 2022-01-04 | Hookipa Biotech Gmbh | Vaccines against hepatitis B virus |
| EP3960197A1 (en) | 2015-11-12 | 2022-03-02 | Hookipa Biotech GmbH | Arenavirus particles as cancer vaccines |
| CA3008437A1 (en) | 2016-01-08 | 2017-07-13 | Vaccibody As | Therapeutic anticancer neoepitope vaccine |
| GB201605210D0 (en) | 2016-03-29 | 2016-05-11 | Oxford Immunotec Ltd | Assay |
| KR20190033483A (ko) * | 2016-06-03 | 2019-03-29 | 이투빅스 코포레이션 | 인간 파필로마바이러스 (hpv)-연관 질환의 치료를 위한 조성물 및 방법 |
| CN106655327A (zh) * | 2016-10-18 | 2017-05-10 | 云南中烟工业有限责任公司 | 一种压缩式充电装置 |
| EP3929770B1 (en) * | 2016-11-11 | 2023-03-22 | Google LLC | Methods, systems, and media for modifying the presentation of video content on a user device based on a consumption of the user device |
| AU2019231654B2 (en) * | 2018-03-06 | 2025-12-11 | Precigen, Inc. | Human papillomavirus vaccines and uses of the same |
| KR102712588B1 (ko) * | 2020-05-25 | 2024-10-02 | (주)진매트릭스 | 사람 파필로마바이러스의 구조적으로 변형된 키메라 폴리펩타이드 및 그 폴리펩타이드를 포함하는 재조합 단백질 및 그 단백질의 용도 |
| WO2021241928A1 (ko) * | 2020-05-25 | 2021-12-02 | (주)진매트릭스 | 사람 파필로마바이러스의 구조적으로 변형된 키메라 폴리펩타이드 및 그 폴리펩타이드를 포함하는 재조합 단백질, 그 단백질의 용도 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9717953D0 (en) * | 1997-08-22 | 1997-10-29 | Smithkline Beecham Biolog | Vaccine |
| JP2002516096A (ja) * | 1998-05-26 | 2002-06-04 | インスティチュート オブ モレキュラー アンド セル バイオロジー | 転写調節に使用するための、ＣＲＥＢ結合タンパク質および関連するｐ３００由来のポリペプチド |
| CN1720060B (zh) | 2002-10-03 | 2011-12-14 | 惠氏控股公司 | 人乳头瘤病毒多肽和免疫原性组合物 |
| TW200844231A (en) | 2007-05-15 | 2008-11-16 | Transgene Sa | Vectors for multiple gene expression |
| WO2010129339A2 (en) * | 2009-04-28 | 2010-11-11 | The Johns Hopkins University | Compositions and methods for enhancing antigen-specific immune responses |
| CN102002105B (zh) * | 2009-09-03 | 2013-01-23 | 中国疾病预防控制中心病毒病预防控制所 | Hpv 16型e7e6融合蛋白基因、表达载体、方法、细胞和用途 |
-
2013
- 2013-01-23 EP EP17185609.9A patent/EP3269387B1/en active Active
- 2013-01-23 ES ES13740950.4T patent/ES2646590T3/es active Active
- 2013-01-23 CN CN201910216555.2A patent/CN110042110A/zh active Pending
- 2013-01-23 HK HK15104469.7A patent/HK1203833A1/xx unknown
- 2013-01-23 DK DK13740950.4T patent/DK2806889T3/da active
- 2013-01-23 US US14/373,844 patent/US9492526B2/en active Active
- 2013-01-23 JP JP2014554791A patent/JP6219849B2/ja active Active
- 2013-01-23 IN IN6118DEN2014 patent/IN2014DN06118A/en unknown
- 2013-01-23 EP EP13740950.4A patent/EP2806889B1/en active Active
- 2013-01-23 CN CN201380012419.2A patent/CN104159607A/zh active Pending
- 2013-01-23 WO PCT/US2013/022696 patent/WO2013112549A1/en not_active Ceased
- 2013-01-23 KR KR1020147023589A patent/KR102195196B1/ko active Active
-
2016
- 2016-09-06 US US15/257,198 patent/US9969779B2/en active Active
-
2017
- 2017-09-28 JP JP2017188121A patent/JP6655051B2/ja active Active
-
2018
- 2018-04-11 US US15/950,819 patent/US20180237477A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015506179A5 (enExample) | ||
| ES2848064T3 (es) | Vacuna terapéutica potenciadora de inmunidad para VPH y enfermedades relacionadas | |
| Pol et al. | Trial watch: oncolytic viruses for cancer therapy | |
| AU2014221143B2 (en) | Vaccine composition | |
| ES3041285T3 (en) | A vaccine for use in the prophylaxis and/or treatment of a disease | |
| JP2016539946A5 (enExample) | ||
| JP2019526580A5 (enExample) | ||
| KR20180119659A (ko) | 항종양 면역을 유도하기 위한 종양 관련 항원의 다중 에피토프를 발현하는 바이러스 벡터 | |
| JP2013507907A5 (enExample) | ||
| JP2016513115A5 (enExample) | ||
| JP2020528911A5 (enExample) | ||
| CN104159607A (zh) | 用于治疗致癌病毒多肽阳性肿瘤的多核苷酸 | |
| CN111154806A (zh) | 一种嵌合外源超级细胞因子的溶瘤病毒载体系统及其在药物中的应用 | |
| JP2018536002A5 (enExample) | ||
| AU2017264901A1 (en) | Combination prime: boost therapy | |
| RU2018123307A (ru) | Вакцинация с использованием альфа3 домена mica/b для лечения рака | |
| JP2017522326A5 (enExample) | ||
| JP2021500880A5 (enExample) | ||
| JP7737141B2 (ja) | 細胞融合を誘導するワクシニアウイルス及びその利用 | |
| JP2017516462A5 (enExample) | ||
| CN102000330B (zh) | 一种核酸疫苗佐剂及其构建方法 | |
| RU2020100072A (ru) | Иммуногенные композиции, содержащие cea, muc1 и tert | |
| WO2024198943A1 (en) | Homologous and heterologous therapeutic vaccination strategies for cancer treatment | |
| CD et al. | Heterologous arenavirus vector prime-boost overrules self-tolerance for efficient tumor-specific CD8 T cell attack | |
| JP2016032439A (ja) | Ｈｔｌｖ−１関連疾患の予防及び／又は治療用ワクチン |